Document is current
Any future updates will be listed below
-
Authors
,
Knop, Stefan
Engelhardt, Monika
Liebisch, Peter
Meisner, Christoph
Holler, Ernst
Metzner, Bernd
Peest, Dietrich
Kaufmann, Martin
Bunjes, Donald
Straka, Christian
Fischer, Thomas
Sezer, Orhan
Hentrich, Marcus
Ostermann, Helmut
Bassermann, Florian
Hess, Georg
Hertenstein, Bernd
Freund, Mathias
Kropff, Martin
Schmidt, Christian A.
Wolf, Hans-Heinrich
Jung, Wolfram
Frickhofen, Norbert
Mielke, Stephan
Bargou, Ralf C.
Maschmeyer, Georg https://orcid.org/0000-0003-2378-2466
Svaldi, Mirija
Langer, Christian H.
Gramatzki, Martin
Hebart, Holger
Kanz, Lothar
Einsele, Hermann
-
Funding
Funding for this research was provided by:
The trial was sponsored by Würzburg University, Würzburg, Germany.
- License Information
-
More Information
Article History
Received: 22 May 2019
Accepted: 29 May 2019
First Online: 28 August 2019
Compliance with ethical standards
:
: MH reports personal fees from Amgen, Celgene, Janssen, Bristol-Myers Squibb, and Takeda. GH reports personal fees from Janssen, Roche, AbbVie, Gilead, Novartis, MorphoSys, and Celgene; and grants from Roche, Pfizer, and Celgene. SM reports non-financial support from EBMT/EHA, IACH, Celgene, Miltenyi, KIADIS, Bellicum, DGHO, Jazz Pharma, and ISCT; and personal fees from Celgene, Miltenyi, KIADIS, Bellicum, and Jazz Pharma. GM reports personal fees from Gilead, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, and Merck-Serono; and non-financial support from Janssen-Cilag. LK reports honoraria for presentation at “MedIpdate” (OnkoUpdate, IntemistenUpdate, PraxisUpdate) and at “Medizin Aktuell”. Amgen and Celgene are sponsors of the “Biannual International Stem Cell Conference, Tübingen, Germany): Scientific chairman: LK. HE reports grants, personal fees, and other (advisory board) from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda. The other authors declare that they have no conflict of interest.
